anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adult intervention arm participants will receive motivational counseling provided by the study staff member enrolling them. The study team member will offer 4 evidence-based treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), emphasizing that the combination is often more effective than one treatment alone, and that they could start treatment even if they are not ready to quit.
A radioactive resin microsphere injection, a preparation method, and a use. Each 1 ml of radioactive resin microsphere injection comprises: 0.1 to 300 mg of radioactive resin microspheres and 1 to 0.75 ml of a hydrogel. The injection is used for the preparation of medications that treat tumors, and can be directly injected into a tumor by interventional means, allowing for direct determination, according to the administration volume, of the radioactive dosage of the radioactive resin microspheres. Hydrogel that has reached inside of the tumor can, together with calcium ions, form a gel inside of the tumor, so that the radioactive resin microspheres can be dispersed relatively uniformly and be limited in the tumor. The radioactive resin microspheres provide high-dosage local radiation therapy to implement the treatment of a solid tumor. The present invention has wide application prospect in solid tumor treatment.
PURPOSE:A cholagogue having high safety and durability of action, containing cinnamic aldehyde as an active ingredient. CONSTITUTION:A cholagogue containing cinnamic aldehyde, a main component of cinnamon oil, as an active ingredient. After cinnamic aldehyde (A) is compared with sodium dehydrocholate (B) in terms of cholagogic action (by Wistar male rat) and acute toxicity (by -Y male mouse) and discussed, B has temporary effect in cholagogic action, and A has excellent cholagogic action and durability. A has >=5,000mg/kg LD50 value, B has 2,050mg/kg LD50 value. A is observed to have high cholagogic action and high safety. An effective dose of cinnamic aldehyde is properly regarded to be 50-100mg per time adult and <=3 times administration daily.
BACKGROUND: There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients.
METHODS: The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patient's medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured.
RESULTS: Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisher's exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications.
CONCLUSION: Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.
Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
OBJECTIVE: Traditional Chinese non-pharmacological therapy has gained popularity in the management of overweight and obesity. This study aims to reveal trends and hotspots of global research on traditional Chinese non-pharmacological therapies for overweight and obesity.
METHODS: Publications on traditional Chinese non-pharmacological therapies for overweight and obesity between 2004 and 2023 were searched from the Web of Science Core Collection. Bibliometric analyses and visualization were performed using VOSviewer, CiteSpace, and R software.
RESULTS: A total of 566 publications from 246 journals were included in this study. Annual number of publications and cited times in the field were generally increasing. China contributed the most publications, followed by the United States and Republic of Korea, and Chengdu University of Traditional Chinese Medicine from China had the highest number of publications among institutions. Stener-Victorin E was not only the most productive author but also, along with Cabioglu MT, the most cited authors. Evidence-Based Complementary and Alternative Medicine was both the largest source journal and the most cited journal. The highly cited references mainly consists of clinical trials, narrative reviews and systematic reviews focusing on acupuncture therapy. Keywords analysis indicated that acupuncture therapy and traditional Chinese exercise constituted the main components of traditional Chinese non-pharmacological therapy in weight management.
CONCLUSIONS: This study revealed a growing interest in traditional Chinese non-pharmacological therapies for managing overweight and obesity, with acupuncture therapies and traditional Chinese exercises as the main research focuses. This study offers insights into traditional Chinese non-pharmacological therapies in weight management, and may benefit further research.
Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
PURPOSE:The titled powder, which contains lecithin, etc., eicosapentaenoic acid based compound, etc. and cyclodextrin, is a precursor for a compound having good palatability, easily handleable, exhibits physiological activity and useful as medicines, healt supplementary foods, etc. CONSTITUTION:Powder containing at least one selected from lecithin, constituent compounds thereof and hydrogenated substances thereof, at least one selected from eicosapentaenoic acid based compounds and derivatives thereof and cyclodextrin. For example, the lecithin is dissolved in the eicosapentaenoic acid based compound under heating. In the process, the amount of the lecithin to be incorporated is preferably >=0.5wt% based on the eicosapentaenoic acid based compound. The cyclodextrin is added to the resultant oily material under stirring, and the resultant mixture is cooled to give the titled powder. The amount of the cyclodextrin to be added is preferably >=3 times that of the eicosapentaenoic acid based compound.
Ibuprofen Lysine is a clear sterile preservative-free solution of the L-lysine salt of (±)-ibuprofen which is the active ingredient. (±)-Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAID). L-lysine is used to create a water-soluble drug product salt suitable for intravenous administration. Each mL of Ibuprofen Lysine contains 17.1 mg of ibuprofen lysine (equivalent to 10 mg of (±)-ibuprofen) in Water for Injection, USP. The pH is adjusted to 7.0 with sodium hydroxide or hydrochloric acid.

The structural formula is:

Ibuprofen Lysine is designated chemically as α-methyl-4-(2-methyl propyl) benzeneacetic acid lysine salt. Its molecular weight is 352.48. Its empirical formula is C19H32N2O4. It occurs as a white crystalline solid which is soluble in water and slightly soluble in ethanol.
BACKGROUND: Post-intensive care syndrome (PICS) is a term coined by the Society of Critical Care Medicine to describe the psychological, cognitive, and physical dysfunction that ICU survivors may experience. Although surgical patients represent a substantial proportion of ICU survivors, studies describing PICS in this specific population remain limited. This study aims to determine the incidence and independent risk factors associated with PICS among surgical ICU survivors in a Chinese cohort.
METHODS: The study was a prospective cohort study of critically ill surgical patients who were discharged from the ICU at the First Affiliated Hospital of Sun Yat-sen University between August 2021 and June 2022. Demographic characteristics, disease-related information, and ICU treatment were collected, and enrolled participants were followed up within six months after ICU discharge. The Chinese version of the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) and the Short Memory Questionnaire (SMQ) were used to assess PICS. The physical component summary (PCS) and the mental component summary (MCS) were averaged from the corresponding four-dimension scores in the SF-36. PICS diagnosis was determined based on the presence of at least one of the following: physiological dysfunction (defined as PCS reductions greater than 10), psychological dysfunction (defined as MCS reductions greater than 10), or cognitive dysfunction (defined as SMQ reductions and scores less than 40 at six months). PICS diagnosis was based on the presence of at least one of the following: physiological, psychological, or cognitive dysfunction.
RESULTS: A total of 565 patients were screened in this study, and 83 were enrolled after applying the inclusion and exclusion criteria. Overall, 65 surgical ICU survivors developed PICS within six months, with an incidence rate of 78.3%. The prevalences were 55.4% and 27.7% at the end of 3 and 6 months after ICU discharge, respectively. Univariate analysis showed that there was a correlation between the occurrence of PICS and the total bilirubin and creatinine levels at ICU admission, APACHE II score, ICU length of stay, and the presence of dialysis (P < 0.05). ICU length of stay was identified as an independent risk factor for the occurrence of PICS in surgical ICU survivors after adjusting for confounders.
CONCLUSION: The overall PICS incidence in surgical ICU survivors was 78.3%, with prevalence gradually decreasing over time to 27.7% within 6 months. For surgical survivors requiring ICU care, the longer the ICU stay, the more likely to develop PICS.
IMPLICATIONS FOR CLINICAL PRACTICE: The findings offer valuable insights into the incidence and risk factors of PICS in surgical ICU survivors, which can help healthcare professionals identify surgical cases at high risk of developing PICS and tailor the treatment effectively.
BACKGROUND: Bariatric surgery is becoming increasingly common and postoperative patients often present to the emergency department (ED) with complications. We sought to describe the presenting complaints, management, and outcomes of postoperative bariatric surgery patients seen in the ED.
METHODS: We conducted a health records review of 300 consecutive postoperative Roux-en-Y bypass surgery patients who presented to two tertiary care EDs of a major bariatric surgery center within one year of surgery. Cases were identified using a data analytic tool, and two evaluators abstracted clinical variables, imaging, treatments, and outcomes using the electronic health record. Attending emergency physicians verified the data and an experienced bariatric surgeon interpreted the computed tomography (CT) results and surgical procedures.
RESULTS: We included 300 patients with mean age 43.0 years, 89.7% female. Of these, 70.0% presented within 30 days of surgery and 41.7% were admitted to hospital. ED treatments included intravenous fluids (67.0%), antiemetics (53.3%), and analgesia (61.9%). Patients presenting within 30 days of surgery were more likely to undergo a CT (74.3% vs 63.3%; p = 0.06) and to have clinically important CT findings (31.9% vs 6.6%; p ≤0.001). More of the ≤30-day patients were admitted to hospital (46.2% vs 31.1%; p = 0.02). While a higher proportion of patients presenting after 30 days underwent a procedure, a large number of those were not directly related to bariatric surgery, such as appendectomy and cholecystectomy. Of the 34 patients undergoing a procedure, the majority presented with abdominal pain (76.5%).
CONCLUSION: This is the first detailed health records review of postoperative bariatric patients seen in the ED in the emergency medicine literature. Those presenting with abdominal pain were more likely to undergo CT abdomen and a surgical procedure. Similarly, those presenting within 30 days of surgery were more likely to have significant CT findings and require hospital admission. Others presenting with primarily nausea and vomiting may improve with ED symptom management and be discharged home with bariatric team follow-up.
BACKGROUND: Dysfunction of retinal vascularization plays pathogenic roles in retinopathy of prematurity (ROP). Hypoxia-inducible factor 1 alpha (HIF1A) is activated by hypoxia and contributes to ROP progression. Herein, we clarified the mechanism underlying HIF1A activation in human retinal vascular endothelial cells (HRECs) under hypoxia.
METHODS: Protein expression was assayed by immunoblot analysis. Cell migration, microtubule formation, invasion, proliferation, and viability were detected by wound-healing, tube formation, transwell, EdU, and CCK-8 assays, respectively. Bioinformatics was used to predict the deubiquitinase-HIF1A interactions and RNA binding proteins (RBPs) bound to USP33. The impact of USP33 on HIF1A deubiquitination was validated by immunoprecipitation (IP) assay. RNA stability analysis was performed with actinomycin D (Act D) treatment. The ELAVL1/USP33 interaction was assessed by RNA immunoprecipitation experiment.
RESULTS: In hypoxia-exposed HRECs, HIF1A and USP33 protein levels were upregulated. Deficiency of HIF1A or USP33 suppressed cell migration, proliferation and microtubule formation of hypoxia-exposed HRECs. Mechanistically, USP33 deficiency led to an elevation in HIF1A ubiquitination and degradation. USP33 deficiency reduced HIF1A protein levels to suppress the proliferation and microtubule formation of hypoxia-induced HRECs. Moreover, the RBP ELAVL1 stabilized USP33 mRNA to increase USP33 protein levels. ELAVL1 decrease repressed the proliferation and microtubule formation of hypoxia-induced HRECs by reducing USP33.
CONCLUSION: Our study identifies a novel ELAVL1/USP33/HIF1A regulatory cascade with the ability to affect hypoxia-induced pathological proliferation, angiogenesis, and migration in HRECs.
Patients receive mosunetuzumab IV, over 2-4 hours, on day 1, 8 and 15 of cycle 1 and day 1 of subsequent cycles. Patients receive etoposide IV, doxorubicin IV, and vincristine IV on days 1-4, cyclophosphamide IV, over 2 hours, on day 5 and prednisone PO BID on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles. Patients undergo bone marrow aspiration and biopsy, tumor biopsy and may undergo echocardiography or MUGA at screening and PET scan, CT scan or MRI and blood sample collection throughout the study.
The study is a retrospective cohort study. The first cohort consists of patients who underwent pancreaticoduodenectomy in year 2015 when intraoperative fluid therapy were managed using goal directed fluid therapy technique. The second cohort consists of patients who underwent pancreaticoduodenectomy in year 2017 when intraoperative fluid therapy were based on the consideration of the anaesthesiologist. In 2015 most of the patients spent the first postoperative night in the ICU where the fluid management and monitoring of the urine output and vital functions were more controlled than in the normal ward. In 2017 most of the patients got in the regular ward right after the surgery. The aim of the study is to examine whether there are differences in the amounts of the intraoperative and postoperative fluids between the cohorts and does the perioperative fluid therapy affect to the complication rates.
To enable a report to be opened by a user other than a doctor-in-charge, and prevent the report from being inadvertently opened.SOLUTION: A browse screen 700 displays the content of a report R1. A requester for the report R1 is a user U1. The profession of a user U3 who requested browsing of the report R1 is an "intern", and is included in the professions "doctor, intern" allowed to open the report R1. However, the user U3 is different from the requester (user U1) for the report R1. Therefore, the user U3 who requested browsing of the report R1 has the right to open the report R1 and is a user other than the doctor in charge of a patient. In this case, when displaying the browse screen 700 in accordance with the request for browsing the report R1, an information processing device displays an inquiry message 701 on the browse screen 700 as to whether or not to put the report R1 in a confirmed state.SELECTED DRAWING: Figure 7
This is a multicenter, open label, dose escalation, Phase I / II study in subjects with relapsed and/or refractory MM. Up to 24 subjects to be enrolled in the Phase I to determine the RP2D. Up to 77 additional evaluable subjects to be enrolled in Phase II for a maximum up to 101 subjects treated in the study. Study centers in the USA and the UK will participate in Phase I and II. Centers in the Philippines will be participating in Phase II only. The planned enrollment period is 22 months and the planned study duration is 28 months.
Group 3- RCT-TVWOD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by temporary restoration (glass ionomer cement) for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
PURPOSE: To obtain the subject agent capable of providing sufficient sustained release effects by using a small amount of a medicine without any side effects such as skin irritancy by blending prescribed amounts of the medicine and a specific percutaneous absorbefacient such as lauric acid diethanolamide in a gum base. CONSTITUTION: This gum type sustained release pharmaceutical preparation is obtained by blending at least any one of N-lauroylsarcosine (salt), lauric acid diethanolamide (salt) and sodium polyoxyethylene lauryl ether phosphate as a percutaneous absorbefacient together with a medicine (e.g. estradiol) in a gum base such as a polymer used as a chewing gum. The amount of the percutaneous absorbefacient to be blended is preferably 0.1-10 pts.wt. based on 100 pts.wt. gum base. The gum type sustained release pharmaceutical preparation is capable of providing sufficient sustained release effects by using a small amount of the medicine. Thereby, stable pharmacodynamic effects can be maintained for a long period. Furthermore, side effects due to the skin irritancy or a sudden rise in blood concentration of the medicine can be suppressed.
Emerging data shows a high prevalence of anxiety during the first several months of the COVID-19 pandemic in the United States. Accordingly, there have been calls for supportive interventions for psychological health during the pandemic. Due to physical distancing requirements, supportive interventions for psychological health will be most accessible if they can be administered remotely. Trauma-informed yoga may support psychological health during the COVID-19 pandemic, but research on remote delivery of trauma-informed yoga is needed. The present study will evaluate the feasibility and acceptability of trauma-informed yoga delivered remotely. In this study, the investigators will create an online delivery platform within REDCap, a secure web application for research, that 1) hosts a 45-minute video of a trauma-informed yoga practice, and 2) collects data on participants' present moment experience of anxiety, mindfulness, and body awareness immediately before and after the yoga practice. Feasibility and acceptability data will allow the investigators to evaluate recruitment methods and refine the delivery method of trauma-informed yoga in a way that aligns with participant preferences. The investigators will also evaluate the short-term effects of trauma-informed yoga on state anxiety, state mindfulness, and body awareness. This study will allow the investigators to pilot the remote delivery of trauma-informed yoga during the ongoing, highly stressful COVID-19 pandemic and further develop trauma-informed yoga as a supportive intervention for psychological health.
Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 4 months.
The present invention relates to a vesicle derived from Weissella sp. bacteria, and uses thereof. The present inventors experimentally confirmed that the vesicle derived from Weissella sp. bacteria effectively inhibits the secretion of inflammatory mediators by pathogenic vesicles which induce inflammation. Therefore, the vesicle derived from Weissella sp. bacteria according to the present invention is expected to be usefully used for developing a composition for preventing, alleviating or treating inflammatory diseases.
Disclosed is a film base for an adhesive patch, which has excellent stretch properties, chemical resistance, flexibility and the like, while being free from decrease in strength and generation of wrinkles due to the swelling of the film base caused by the affects of an adhesive layer that contains a medicine and the like, when the film base is used for an adhesive patch. The film base for an adhesive patch also exhibits excellent adhesion to the adhesive layer that contains a medicine and the like, and fits well on the body. Also disclosed is an adhesive patch using the film base for an adhesive patch. Specifically disclosed is a film base for an adhesive patch, which is obtained by forming a water-swellable polyurethane layer on one surface of an elastomer layer. The film base for an adhesive patch is characterized by having a stress at 10% elongation (a 10% modulus) of 0. 2-3. 0 N/25 mm, a 20% modulus of 0. 3-4. 0 N/25 mm, and a 50% modulus of 0. 5-5. 0 N/25 mm.